Analysts' Recommendation: Buy 30 Days Ago: Strong Buy Analysts' Target: $11 Analysts' Targets Stanford Group Company $6 Buy Monday, June 16, 2008 MDB Capital Group $15 Buy Monday, January 07, 2008 Maxygen, Inc., a biotechnology company, engages in the discovery, development, and commercialization of protein pharmaceuticals for treatment of disease and serious medical conditions in the United States. The company’s product candidates comprises MAXY-G34, a granulocyte colony stimulating factor that is in Phase IIa clinical trial for the treatment of neutropenia; MAXY-VII, a factor VIIa product that is in pre-clinical stage for the treatment of hemophilia and acute bleeding conditions; and MAXY-4, a CTLA-4-Ig product for the treatment of rheumatoid arthritis and other immune or autoimmune diseases. It has a strategic alliance with Roche Holdings, Ltd. for the development and commercialization of Maxygen's portfolio of next-generation interferon alpha and beta variants for a range of indications. The company was founded in 1996 and is headquartered in Redwood City, California.
$4.53 (07/12/08)
